Nanocarriers for lung inflammation therapy
US12221471B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 18, 2019 |
| Grant date | Feb 11, 2025 |
| Priority date | — |
| Expiry date | Jul 11, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/5176
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are lung-targeted extracellular vesicles (EVs) loaded with an anti-inflammatory cargo, as well as compositions, systems, and methods for making same. The disclosed EVs can contain a lung targeted ligand, such as a fusion protein containing a lung targeting moiety. Also disclosed is a composition comprising an EV containing the disclosed fusion protein. In some embodiments, the EV is loaded with an anti-inflammatory cargo. Also disclosed is an EV-producing cell engineered to produce the disclosed EVs. Also disclosed is a method for making the disclosed EVs that involves culturing the disclosed EV-producing cells under conditions suitable to produce EVs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.